People taking Ozempic and Wegovy, which contain the drug semaglutide, may be at an increased risk of developing a ...

Extensive Scientific Evidence Supporting Growth Factor Receptor Bound Protein-2 (Grb2) as Fundamental Link in Insulin ResistanceReallocates ...

The top 5 most-viewed content from this year's American Society for Preventive Cardiology (ASPC) Congress on Cardiovascular ...

Progress in assessing cardiovascular risk and identifying early prevention opportunities, improvements in treating heart failure, new therapies for bleeding strokes, strategies for reducing the ...

The fact you could click a link in my bio and go buy medication is beyond me ... septic shock and pancreatitis after taking ...

The European Medicines Agency has allowed Eli Lilly to update the product label of its weight-loss drug Mounjaro to show it ...

Less than three months after going public via a $227.7 million IPO, shares of Bioage Labs Inc. (NASDAQ:BIOA) took a hit Dec. 9, losing 77% of their value, as safety concerns prompted the company to ...

Tirzepatide treatment led to a 47% greater relative reduction in weight compared with semaglutide. Topline results were announced from a phase 3b clinical trial comparing tirzepatide with ...

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, the first to show a benefit on ...

After hours: December 10 at 5:50:04 PM EST ...